US Edition
News from curetoday.com
We’ve assigned a media bias rating of unknown to curetoday.com. You can read more about our methodology here.
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top curetoday.com News
United States · United StatesFDA clears expanded use of AKEEGA as the first PARP-based precision combo for BRCA2-mutated mCSPC, cutting progression or death 54 percent and delaying symptoms 59 percent in Phase 3.See the Story
Johnson & Johnson (NYSE: JNJ) Gets FDA OK; AKEEGA Delays BRCA2 mCSPC Progress 59 Percent
61% Center coverage: 36 sources
FDA · United States(MedPage Today) -- The FDA approved trastuzumab deruxtecan (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
Approval was based on results...See the Story
AstraZeneca, Daiichi's breast cancer drug gets FDA nod as first-line treatment
80% Center coverage: 10 sources
